OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Oct 4, 2013

Keywords

ClinConnect Summary

OPTImal Management of Antithrombotic agents: OPTIMA-2 trial

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the foundation antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI). Clopidogrel is the most commonly used P2Y12 receptor inhibitor worldwide because it is effective and inexpensive1. High on-treatment platelet reactivity (HOPR) occurs in as many as one-third of patients treated with standard dose clopidogrel (75mg once daily), and is associated with an increased risk of major adverse cardiovascular events (MACE).

Vario...

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Successively recruit all patients who receive stent implantation;
• • 2. Intended use of standard DAPT with the combination of aspirin 100mg once daily and clopidogrel 75mg once daily for at least 12 months;
• • 3. Patient aged \>18 years and ≦80 years old;
• • 4. Signed inform consent.
• Exclusion criteria:
• • 1. Allergy or intolerance to study drugs;
• • 2. History of gastrointestinal or intracranial bleeding;
• • 3. Need for anticoagulant therapy;
• • 4. High risk of bleeding (e.g., myelodysplasia, baseline platelet count \< 80 × 109/L);
• • 5. Hemoglobin \< 90g/L;
• • 6. Active malignancy or life expectancy \< 1 year;
• • 7. Patients with other conditions made them unsuitable to be recruited at the discretion of the investigators.